Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: serotonergic involvement

RGS2 is a primary terminator of β2-adrenergic receptor-mediated Gi signaling

(2011) Khalid Chakir et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Antidepressant-like properties of α2-containing GABAA receptors

(2010) Isabel Vollenweider et al.   BEHAVIOURAL BRAIN RESEARCH

Learning as a Model for Neural Plasticity in Major Depression

(2010) Christoph Nissen et al.   BIOLOGICAL PSYCHIATRY

Depression-resistant endophenotype in mice overexpressing cannabinoid CB2 receptors

(2010) MS García-Gutiérrez et al.   BRITISH JOURNAL OF PHARMACOLOGY

Evidence for enhanced M3 muscarinic receptor function and sensitivity to atrial arrhythmia in the RGS2-deficient mouse

(2009) Jari M. Tuomi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Influence of RGS2 on Anxiety-Related Temperament, Personality, and Brain Function

(2008) Jordan W. Smoller et al.   ARCHIVES OF GENERAL PSYCHIATRY

RGS2and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults

(2008) Karestan C. Koenen et al.   DEPRESSION AND ANXIETY

Social approach in genetically engineered mouse lines relevant to autism

(2008) S. S. Moy et al.   GENES BRAIN AND BEHAVIOR

Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease

(2008) Terence Y.C. Pang et al.   HUMAN MOLECULAR GENETICS

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region

(2008) L Greenbaum et al.   PHARMACOGENOMICS JOURNAL

Addictive drugs modulate GIRK-channel signaling by regulating RGS proteins

(2008) Marta Lomazzi et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies

(2007) Megan E. Kozisek et al.   PHARMACOLOGY & THERAPEUTICS